Ergocalciferol supplementation in hemodialysis patients with Vitamin D deficiency: A randomized clinical trial

Journal of the American Society of Nephrology

Volumn 27, Issue 6, 2016, Pages 1801-1810

  Miskulin, Dana C ^a,b   Majchrzak, Karen ^c   Tighiouart, Hocine ^a,b   Muther, Richard S ^d   Kapoian, Toros ^e,f   Johnson, Doug S ^c   Weiner, Daniel E ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Dialysis Clinic Inc   (United States)

^d Infectious Disease Associates of Kansas City   (United States)

^e Dialysis Clinics Inc   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; RECOMBINANT ERYTHROPOIETIN; VITAMIN;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; DIETARY SUPPLEMENT;

DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; HUMANS; MIDDLE AGED; RENAL DIALYSIS; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84991434587     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015040468     Document Type: Article

References (48)

1. Lambert PW, Stern PH, Avioli RC, Brackett NC, Turner RT, Greene A, Fu IY, Bell NH: Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69: 722-725, 1982
2. Adams JS, Hewison M: Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 523: 95-102, 2012
3. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, FukagawaM, Frimat L,Mendelssohn DC, Port FK, Pisoni RL, Robinson BM: Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin J Am Soc Nephrol 10: 98-109, 2015
4. Singer RF: Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin Dial 26: 40-46, 2013
5. Kidney Disease: Improving Global Outcomes CKDMBDWG: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl 113: S1-S130, 2009
6. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T,Gil C, Cortez J, Ferreira A: Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5: 905-911, 2010
7. Kumar VA, Kujubu DA, Sim JJ, Rasgon SA, Yang PS: Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol 24: 98-105, 2011
8. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: c132-c138, 2007
9. Andress DL: Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 69: 33-43, 2006
10. Kendrick J, Targher G, Smits G, Chonchol M: 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 30: 64-72, 2009
11. Kiss Z, AmbrusC, AlmasiC, Berta K, Deak G,Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, Nemeth Z, Szabo A, Mucsi I: Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 117: c373-c378, 2011
12. Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M: Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 77: 715-720, 2010
13. Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C: Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo. Nephron Clin Pract 95: c121-c127, 2003
14. Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M: Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation. Nephrol Dial Transplant 28: 1672-1679, 2013
15. Zughaier SM, Alvarez JA, Sloan JH, Konrad RJ, Tangpricha V: The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol 1: 19-25, 2014
16. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 373: 1532-1542, 2009
17. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, GrazianoG,McGee R, Nicolucci A, Tognoni G, Strippoli GF: Meta-analysis: erythropoiesisstimulating agents in patients with chronic kidney disease. Ann Intern Med 153: 23-33, 2010
18. Jean G, Souberbielle JC, Chazot C: Monthly cholecalciferol administration in haemodialysis patients: A simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24: 3799-3805, 2009
19. Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R: 25-HydroxyvitaminDresponse to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 7: 1428-1434, 2012
20. González EA, Sachdeva A,Oliver DA,Martin KJ: VitaminD insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24: 503-510, 2004
21. Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ: Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 8: 1143-1149, 2013
22. Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M, Wissing KM, Nortier JL: Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am J Kidney Dis 64: 696-705, 2014
23. Mose FH, VaseH, Larsen T, Kancir AS, Kosierkiewic R, Jonczy B, Hansen AB, Oczachowska-Kulik AE, Thomsen IM, Bech JN, Pedersen EB: Cardiovascular effects of cholecalciferol treatment in dialysis patients-A randomized controlled trial. BMC Nephrol 15: 50, 2014
24. Seibert E, Heine GH, Ulrich C, Seiler S, Köhler H, Girndt M: Influence of cholecalciferol supplementation in hemodialysis patients onmonocyte subsets: A randomized, double-blind, placebo-controlled clinical trial. Nephron Clin Pract 123: 209-219, 2013
25. Shirazian S, Schanler M, Shastry S, Dwivedi S, Kumar M, Rice K, Miyawaki N, Ghosh S, Fishbane S: The effect of ergocalciferol on uremic pruritus severity: A randomized controlled trial. J RenNutr 23: 308-314, 2013
26. Piñera-Haces C, Izquierdo-Ortiz MJ,Martín-de Francisco AL, García-Unzueta MT, López-Hoyos M, Toyos C, Allende N, Quintela E, Arias M: Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. Nefrologia 33: 77-84, 2013
27. Wasse H,Huang R, LongQ, Singapuri S, Raggi P, Tangpricha V: Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr 95: 522-528, 2012
28. Autier P, Boniol M, Pizot C, Mullie P: Vitamin D status and ill health: A systematic review. Lancet Diabetes Endocrinol 2: 76-89, 2014
29. ManginM, Sinha R, Fincher K: Inflammation and vitamin D: The infection connection. Inflamm Res 63: 803-819, 2014
30. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543-1551, 2010
31. Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, Nybo M, Rasmussen LM, Hansen D, Scholze A: Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 27: 3523-3531, 2012
32. Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL, Chugh S, Deshpande S, Ford C, Gama R: Vitamin D: A negative acute phase reactant. J Clin Pathol 66: 620-622, 2013
33. Delanaye P, Weekers L, Warling X, Moonen M, Smelten N, Médart L, Krzesinski JM, Cavalier E: Cholecalciferol in haemodialysis patients: A randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 28: 1779-1786, 2013
34. Rianthavorn P, Boonyapapong P: Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. Pediatr Nephrol 28: 1261-1266, 2013
35. Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, Ankers E, Wenger J, Tucker JK, Trottier C, Pathan F, Kalim S, Nigwekar SU, Thadhani R: Nutritional vitamin D supplementation in dialysis: A randomized trial. Clin J Am Soc Nephrol 10: 611-619, 2015
36. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V: Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study. Endocr Pract 14: 10-17, 2008
37. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S: Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial. Am J Kidney Dis 59: 58-66, 2012
38. Palmer SC,McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF: Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev (4): CD005633, 2009
39. Pipili C, Dimitriadis C, Sekercioglu N, Bargman JM, Oreopoulos DD: Effect of nutritional vitamin D preparations on parathyroid hormone in patients with chronic kidney disease. Int Urol Nephrol 44: 167-171, 2012
40. Norman PE, Powell JT: Vitamin D and cardiovascular disease. Circ Res 114: 379-393, 2014
41. Mao PJ, ZhangC, Tang L, Xian YQ, Li YS,WangWD, Zhu XH,QiuHL,He J, Zhou YH: Effect of calcium or vitamin D supplementation on vascular outcomes: A meta-analysis of randomized controlled trials. Int J Cardiol 169: 106-111, 2013
42. Bolland MJ, Grey A, Gamble GD, Reid IR: The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: A trial sequential meta-analysis. Lancet Diabetes Endocrinol 2: 307-320, 2014
43. Nigwekar SU, Bhan I, Thadhani R: Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60: 139-156, 2012
44. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC: Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA 303: 1815-1822, 2010
45. BollandMJ,Grey A: Are trials of vitamin D with mortality as an endpoint really needed? BMJ 349: g4452, 2014
46. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 9: CD004289, 2013
47. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R: Vitamin D-binding protein and vitaminD status of black Americans and white Americans. N Engl JMed 369: 1991-2000, 2013
48. Daugirdas JT, Finn WF, Emmett M, Chertow GM; Frequent Hemodialysis Network Trial Group: The phosphate binder equivalent dose. Semin Dial 24: 41-49, 2011